First National Bank Sioux Falls Purchases 161 Shares of Johnson & Johnson (NYSE:JNJ)


Share on StockTwits

First National Bank Sioux Falls boosted its position in Johnson & Johnson (NYSE:JNJ) by 3.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,542 shares of the company’s stock after purchasing an additional 161 shares during the quarter. Johnson & Johnson comprises about 1.6% of First National Bank Sioux Falls’ portfolio, making the stock its 15th biggest holding. First National Bank Sioux Falls’ holdings in Johnson & Johnson were worth $911,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Bank of New York Mellon Corp lifted its holdings in shares of Johnson & Johnson by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock worth $5,029,590,000 after buying an additional 1,628,229 shares in the last quarter. Norges Bank acquired a new stake in Johnson & Johnson in the 4th quarter worth about $4,370,566,000. Morgan Stanley boosted its holdings in Johnson & Johnson by 7.3% in the 4th quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock valued at $3,794,594,000 after purchasing an additional 1,638,263 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Johnson & Johnson by 4.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 17,236,904 shares of the company’s stock worth $2,712,680,000 after purchasing an additional 692,267 shares in the last quarter. Finally, California Public Employees Retirement System increased its holdings in shares of Johnson & Johnson by 9.7% during the fourth quarter. California Public Employees Retirement System now owns 11,649,355 shares of the company’s stock worth $1,833,375,000 after purchasing an additional 1,032,575 shares during the period. 67.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson stock traded down $2.84 during midday trading on Tuesday, hitting $158.80. 146,904 shares of the company traded hands, compared to its average volume of 8,088,733. The firm’s fifty day moving average price is $160.81 and its 200-day moving average price is $154.79. The stock has a market cap of $418.07 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 12 month low of $133.65 and a 12 month high of $173.65. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.24 and a current ratio of 1.48.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Monday, January 25th. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.82 by $0.04. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $21.62 billion. During the same quarter in the previous year, the firm posted $1.88 earnings per share. The company’s revenue was up 8.7% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 7.99 earnings per share for the current year.

A number of equities research analysts recently issued reports on the company. SVB Leerink increased their price target on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 27th. Cantor Fitzgerald increased their target price on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, January 26th. Morgan Stanley boosted their price target on Johnson & Johnson from $178.00 to $187.00 and gave the company an “overweight” rating in a research note on Wednesday, January 27th. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $157.00 to $175.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 27th. Finally, Cowen boosted their target price on shares of Johnson & Johnson from $170.00 to $195.00 and gave the company an “outperform” rating in a research report on Wednesday, January 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Buy” and an average target price of $178.60.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also: Yield Curve

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.